MMED
Get informed when a big investor buys or sells
+ FollowUndervalued by 111.5% based on the discounted cash flow analysis.
| Market cap | $6.12 Billion |
|---|---|
| Enterprise Value | $5.97 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.29 |
| Beta | -3.71 |
| Outstanding Shares | 281,000,000 |
| P/E Ratio | -19.81 |
|---|---|
| PEG | 19.81 |
| Price to Sales | 1.93 |
| Price to Book Ratio | 1.77 |
| Enterprise Value to Revenue | 1.87 |
| Enterprise Value to EBIT | -542.87 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.9956▲ 499.56% |
|---|---|
| Total Calls | 45,400▲ Infinity% |
| Total Puts | 226,800▲ 219.44% |
Holdings and activity of institutional investors.
| Ownership % | 13.34%▲ 0.69% |
|---|---|
| Total Invested | $560.52M▲ 15.72% |
| Investors Holding | 105▲ 45.00% |
No data
MiniMed Group, Inc. engages in the development, manufacturing, and marketing of a wide range of medical devices and solutions for diabetes management. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion s...